JP2025013884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025013884A5 JP2025013884A5 JP2024182581A JP2024182581A JP2025013884A5 JP 2025013884 A5 JP2025013884 A5 JP 2025013884A5 JP 2024182581 A JP2024182581 A JP 2024182581A JP 2024182581 A JP2024182581 A JP 2024182581A JP 2025013884 A5 JP2025013884 A5 JP 2025013884A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- foxp3
- homology
- gene
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663545P | 2018-04-27 | 2018-04-27 | |
| US62/663,545 | 2018-04-27 | ||
| PCT/US2019/029082 WO2019210042A1 (en) | 2018-04-27 | 2019-04-25 | Expression of foxp3 in edited cd34+ cells |
| JP2020560400A JP7575950B2 (ja) | 2018-04-27 | 2019-04-25 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560400A Division JP7575950B2 (ja) | 2018-04-27 | 2019-04-25 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025013884A JP2025013884A (ja) | 2025-01-28 |
| JP2025013884A5 true JP2025013884A5 (enExample) | 2025-04-10 |
| JP7844582B2 JP7844582B2 (ja) | 2026-04-13 |
Family
ID=68294731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560400A Active JP7575950B2 (ja) | 2018-04-27 | 2019-04-25 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
| JP2024182581A Active JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560400A Active JP7575950B2 (ja) | 2018-04-27 | 2019-04-25 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11713459B2 (enExample) |
| EP (1) | EP3784690A4 (enExample) |
| JP (2) | JP7575950B2 (enExample) |
| CN (1) | CN112218882A (enExample) |
| AU (2) | AU2019261438B2 (enExample) |
| CA (1) | CA3091688A1 (enExample) |
| IL (1) | IL277039A (enExample) |
| SG (1) | SG11202007878UA (enExample) |
| WO (1) | WO2019210042A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016427822B2 (en) | 2016-10-31 | 2025-01-23 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogennous FOXP3 gene |
| CA3091491A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of human foxp3 in gene edited t cells |
| CA3091688A1 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of foxp3 in edited cd34+ cells |
| KR20210116531A (ko) * | 2019-01-18 | 2021-09-27 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 영양 장애형 표피 수포증 치료약 |
| JP2022533713A (ja) | 2019-05-21 | 2022-07-25 | サンガモ セラピューティクス， インコーポレイテッド | 調節性ｔ細胞における制御された導入遺伝子発現 |
| CA3145037A1 (en) * | 2019-06-27 | 2020-12-30 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Artificial antigen-specific immunoregulatory t (airt) cells |
| US20220380727A1 (en) | 2019-11-08 | 2022-12-01 | Sangamo Therapeutics, Inc. | Generation of engineered regulatory t cells |
| WO2021144692A1 (en) * | 2020-01-14 | 2021-07-22 | Crispr Therapeutics Ag | Methods for increased efficiency of homology-directed repair |
| CA3168089A1 (en) * | 2020-02-13 | 2021-08-19 | Rosa Bacchetta | Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients |
| AU2021368557A1 (en) * | 2020-10-27 | 2023-06-08 | Adoc Ssf, Llc | Compositions and methods for the treatment of cancer using next generation engineered t cell therapy |
| CN112851794B (zh) * | 2021-02-04 | 2023-05-23 | 苏州铂维生物科技有限公司 | 一种基于cd271的抗原表位及其应用 |
| GB202113674D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| GB202113673D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9006701A (en) | 2000-09-20 | 2002-04-02 | Cobra Therapeutics Ltd | Polynucleotide |
| ATE405586T1 (de) | 2001-05-08 | 2008-09-15 | Darwin Molecular Corp | Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins |
| GB0614536D0 (en) | 2006-07-21 | 2006-08-30 | Metcalfe Susan M | Methods of controlling cellular response to LIF |
| EP2064350B1 (en) * | 2006-11-27 | 2013-01-02 | Ludwig Institute for Cancer Research Ltd. | Expression of foxp3 by cancer cells |
| HUE030386T2 (en) | 2007-01-31 | 2017-05-29 | Yeda Res & Dev | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| AU2007347364A1 (en) * | 2007-02-21 | 2008-08-28 | Adelaide Research & Innovation Pty Ltd | Method for obtaining TREG-cells |
| WO2008141282A2 (en) | 2007-05-11 | 2008-11-20 | The Regents Of The University Of Michigan | Materials and methods for foxp3 tumor suppression |
| US8846308B2 (en) | 2007-06-08 | 2014-09-30 | The Trustees Of The University Of Pennsylvania | Method for identifying immune response modulators |
| JP2011503232A (ja) | 2007-11-20 | 2011-01-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 免疫応答の調節 |
| CA2717166A1 (en) | 2008-03-03 | 2009-09-19 | Converge Biotech Inc. | Methods of modulating t cell-dependent immune responses |
| WO2012018930A1 (en) | 2010-08-03 | 2012-02-09 | University Of Miami | Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy |
| WO2014180943A1 (en) | 2013-05-08 | 2014-11-13 | Vib Vzw | Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders |
| RU2725542C2 (ru) | 2013-05-13 | 2020-07-02 | Селлектис | Способы конструирования высокоактивных т-клеток для иммунотерапии |
| ES2883131T3 (es) * | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| DK3309248T3 (da) | 2013-05-29 | 2021-08-02 | Cellectis | Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system |
| AU2015216875B2 (en) | 2014-02-14 | 2021-02-25 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| AU2015233347A1 (en) | 2014-03-21 | 2016-09-08 | Cellectis | Engineering mammalian genome using DNA-guided Argonaute interference systems (DAIS) |
| KR101835554B1 (ko) | 2014-06-24 | 2018-04-19 | 서울대학교 산학협력단 | C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법 |
| AU2016206870B2 (en) | 2015-01-12 | 2022-02-17 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
| ES2880473T5 (es) * | 2015-01-30 | 2024-05-09 | Univ California | Suministro de proteínas en células hematopoyéticas primarias |
| CA2988854A1 (en) * | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| WO2018031762A1 (en) | 2016-08-10 | 2018-02-15 | Duke University | Compositions, systems and methods for programming immune cell function through targeted gene regulation |
| WO2018035141A1 (en) * | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
| WO2018073391A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| CN111344396A (zh) * | 2016-10-27 | 2020-06-26 | 因提玛生物科学公司 | 制备遗传修饰细胞的病毒方法 |
| AU2016427822B2 (en) | 2016-10-31 | 2025-01-23 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogennous FOXP3 gene |
| CN118546256A (zh) | 2016-12-13 | 2024-08-27 | 西雅图儿童医院（Dba西雅图儿童研究所） | 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法 |
| CN109797171A (zh) | 2017-05-08 | 2019-05-24 | 北京东方略细胞技术有限公司 | 经修饰的t细胞、其制备方法及用途 |
| JP7290288B2 (ja) * | 2017-08-22 | 2023-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でｆｏｘｐ３を発現するレンチウイルスベクター |
| CA3091688A1 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of foxp3 in edited cd34+ cells |
| CA3091491A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of human foxp3 in gene edited t cells |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
-
2019
- 2019-04-25 CA CA3091688A patent/CA3091688A1/en active Pending
- 2019-04-25 JP JP2020560400A patent/JP7575950B2/ja active Active
- 2019-04-25 US US16/981,223 patent/US11713459B2/en active Active
- 2019-04-25 WO PCT/US2019/029082 patent/WO2019210042A1/en not_active Ceased
- 2019-04-25 AU AU2019261438A patent/AU2019261438B2/en active Active
- 2019-04-25 CN CN201980028370.7A patent/CN112218882A/zh active Pending
- 2019-04-25 EP EP19793428.4A patent/EP3784690A4/en active Pending
- 2019-04-25 SG SG11202007878UA patent/SG11202007878UA/en unknown
-
2020
- 2020-08-31 IL IL277039A patent/IL277039A/en unknown
-
2023
- 2023-06-16 US US18/336,276 patent/US20240117352A1/en active Pending
-
2024
- 2024-10-18 JP JP2024182581A patent/JP7844582B2/ja active Active
- 2024-11-22 AU AU2024266824A patent/AU2024266824A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025013879A5 (enExample) | ||
| JP2020518276A5 (enExample) | ||
| JP2021526853A5 (enExample) | ||
| Ehrke-Schulz et al. | CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes | |
| JP7844582B2 (ja) | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 | |
| Li et al. | Adenovirus vectors in hematopoietic stem cell genome editing | |
| Di Matteo et al. | Recent developments in transposon-mediated gene therapy | |
| JP2025170240A5 (enExample) | ||
| JP2019115348A5 (enExample) | ||
| JP2021518139A5 (enExample) | ||
| JP2022546608A5 (enExample) | ||
| US20180163188A1 (en) | Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA | |
| HK1223401A1 (zh) | 用於治疗遗传病状的方法和组合物 | |
| JP2022519595A5 (enExample) | ||
| JP2022516130A5 (enExample) | ||
| JP2023533417A5 (enExample) | ||
| IL295858B1 (en) | gRNA molecules including TRACR and crRNA, compositions containing them and their use | |
| JP2018516978A5 (enExample) | ||
| JP2021521849A5 (enExample) | ||
| JP2021520800A5 (enExample) | ||
| US20190241911A1 (en) | Engineered guide rna and uses thereof | |
| CN113195001B (zh) | 重组细小病毒载体及其制备方法和用途 | |
| JP2021502077A5 (enExample) | ||
| JP7765377B2 (ja) | Ｈｕｈエンドヌクレアーゼを用いた標的化ゲノム修飾を促進するための方法及び組成物 | |
| JP2020511931A5 (enExample) |